Rapid cognitive screening in multiple sclerosis accomplished by the Free Recall and Recognition Test

2007 ◽  
Vol 13 (2) ◽  
pp. 272-274 ◽  
Author(s):  
Im Claesson ◽  
C Ytterberg ◽  
S Johansson ◽  
O Almkvist ◽  
L Von Koch
Keyword(s):  
Multiple Sclerosis ◽  
Cognitive Impairment ◽  
Free Recall ◽  
Disease Severity ◽  
Recognition Test ◽  
Screening Tool ◽  
Cognitive Tests ◽  
Cognitive Screening ◽  
Severity Rating ◽  
Serial Addition

This study sought to investigate the feasibility of the Free Recall and Recognition Test (FRRT) as a practical screening tool for cognitive impairment in multiple sclerosis (MS). Persons with MS (n =227) were consecutively recruited and assessed with four cognitive tests; FRRT, Symbol Digit Modalities Test (SDMT), Paced Auditory Serial Addition Test (PASAT), and the Mini-Mental State Examination (MMSE). Disease severity was assessed by the Expanded Disability Status Scale (EDSS). The FRRT, which was completed by 99% of the cohort in approximately 5 minutes per assessment, correlated significantly with the other cognitive tests, as well as with the disease severity rating. A cut-off of 4 for the FRRT recall rendered 90% sensitivity and 25% specificity, and a cut-off of 4.2 for the FRRT recognition resulted in 70% sensitivity and 51% specificity. We conclude that the FRRT proved feasible as a practical screening tool for cognitive impairment in MS within a clinical setting. Multiple Sclerosis 2007; 13: 272–274. http://msj.sagepub.com

Cognitive impairment in multiple sclerosis

2021 ◽  
Vol 17 (Sup1) ◽  
pp. S16-S22
Author(s):  
Jennifer Slough ◽  
Wallace Brownlee
Keyword(s):  
Quality Of Life ◽  
Multiple Sclerosis ◽  
Cognitive Impairment ◽  
Cognitive Tests

Cognitive impairment is a common but under-diagnosed symptom in people with multiple sclerosis (MS). Cognitive impairment is important to consider as it can have a big impact on quality of life (QoL) for people with MS and, although easily identified in clinic with simple cognitive tests, these are not routinely done. From a nursing perspective, it is important to be aware of how to manage cognitive impairment in MS. Jennifer Slough and Wallace Brownlee explain.

Is the Clock Drawing Test a screening tool for the diagnosis of mild cognitive impairment? A systematic review

2009 ◽  
Vol 22 (1) ◽  
pp. 56-63 ◽  
Author(s):  
Lena Ehreke ◽  
Melanie Luppa ◽  
Hans-Helmut König ◽  
Steffi G. Riedel-Heller
Keyword(s):  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Literature Search ◽  
Screening Tool ◽  
Cognitive Screening ◽  
Clock Drawing Test ◽  
Clock Drawing ◽  
Drawing Test ◽  
Diagnosis Of Dementia ◽  
Mean Differences

ABSTRACTBackground:The clock drawing test (CDT) is a common and widely used cognitive screening instrument for the diagnosis of dementia. However, it has remained unclear whether it is a suitable method to identify mild cognitive impairment (MCI). The aim of this paper is to review systematically the studies concerning the utility of the CDT in diagnosing MCI.Method:A systematic literature search was conducted. All studies dealing with utility of CDT in diagnosing MCI regardless of the applied CDT scoring system and MCI concept were selected.Results:Nine relevant studies were identified. The majority of the studies compared average CDT scores of cognitively healthy and mildly impaired subjects, and four of them identified significant mean differences. If reported, sensitivity and specificity have been mostly unsatisfactory.Conclusion:CDT should not be used for MCI-screening.

Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial

2010 ◽  
Vol 16 (6) ◽  
pp. 715-723 ◽  
Author(s):  
JF Lovera ◽  
E. Frohman ◽  
TR Brown ◽  
D. Bandari ◽  
L. Nguyen ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cognitive Impairment ◽  
Free Recall ◽  
Controlled Trial ◽  
Neuropsychiatric Symptoms ◽  
Verbal Learning ◽  
Self Report ◽  
California Verbal Learning Test ◽  
Cognitive Improvement ◽  
Learning Test

Background: Memantine, an NMDA antagonist, is effective for moderate to severe Alzheimer’s disease. Objective: Determine whether memantine improves cognitive performance (CP) among subjects with multiple sclerosis (MS) and cognitive impairment (CI). Methods: This double-blind, randomized, placebo-controlled trial (Clinicaltrials.gov NCT00300716) compared memantine 10 mg twice a day (4 week titration followed by 12 weeks on the highest tolerated dose) with placebo. The primary outcome was the change from baseline to exit on the Paced Auditory Serial Addition Test (PASAT) and the California Verbal Learning Test-II (CVLT-II) Long Delay Free Recall (LDFR). Secondary outcomes included additional neuropsychological tests; self-report measures of quality of life, fatigue, and depression; and family/caregiver reports of subjects’ CI and neuropsychiatric symptoms. Results: The differences between the groups on the change on the PASAT (placebo—memantine = 0.0 correct responses, 95% CI 3.4, 3.4; p = 0.9) and on CVLT-II LDFR (placebo—memantine =—0.6 words, 95% CI —2.1, 0.8; p = 0.4) as well as on the other cognitive tests were not significant. Subjects on memantine had no serious adverse events (AEs) but had more fatigue and neurological AEs as well as, per family members’ reports, less cognitive improvement and greater neuropsychiatric symptoms than subjects on placebo. Conclusion: Memantine 10 mg twice a day does not improve CP in subjects with MS, ages 18—65, without major depression, who have subjective cognitive complaints and perform worse than one SD below the mean on the PASAT or on the California Verbal Learning Test-II (total recall or delayed free recall).

scholarly journals Validation of the Guy's Neurological Disability Scale as a screening tool for cognitive impairment in multiple sclerosis

2019 ◽  
Vol 35 ◽  
pp. 272-275
Author(s):  
Ritsu Akatani ◽  
Norio Chihara ◽  
Hisatsugu Tachibana ◽  
Shusuke Koto ◽  
Hisatomo Kowa ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cognitive Impairment ◽  
Screening Tool ◽  
Neurological Disability ◽  
Disability Scale

A short version of Rao's Brief Repeatable Battery as a screening tool for cognitive impairment in multiple sclerosis

2009 ◽  
Vol 23 (2) ◽  
pp. 268-275 ◽  
Author(s):  
E. Portaccio ◽  
B. Goretti ◽  
V. Zipoli ◽  
G. Siracusa ◽  
S. Sorbi ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cognitive Impairment ◽  
Screening Tool ◽  
Short Version ◽  
Repeatable Battery

Comparison of two brief neuropsychological batteries in people with multiple sclerosis

2002 ◽  
Vol 8 (2) ◽  
pp. 169-176 ◽  
Author(s):  
A Solari ◽  
L Mancuso ◽  
A Motta ◽  
L Mendozzi ◽  
C Serrati
Keyword(s):  
Multiple Sclerosis ◽  
Cognitive Impairment ◽  
Poor Performance ◽  
Clinical Variable ◽  
Impaired Performance ◽  
Selective Reminding ◽  
Administration Time ◽  
Serial Addition ◽  
The Relationship ◽  
Serial Evaluation

Background: We compared two brief neuropsychological batteries devised to assess people with multiple sclerosis (MS) and used them to assess the relationship between cognitive impairment and clinical characteristics. Methods: We administered either the Brief Repeatable Battery of Neuropsychological Tests (BRBNT) or the Screening Examination for Cognitive Impairment (SEFCI) to 213 consecutive MS outpatients and 213 individually matched controls. Results: Administration times were longer for BRBNT than SEFCI, for MS and controls (p=0.001). People with MS had lower scores in all individual tests than controls (p<0.001, BRBNT and SEFCI). By the criterion of poor performance on one or more tests, the sensitivity of BRBNT was 41.9% and that of SEFCI 31.5%. The corresponding figures by poor performance on two or more tests were 16.2% for BRBNT and 18.5% for SEFCI. The Buschke Selective Reminding and Paced Auditory Serial Addition were the tests best discriminating between people with MS and controls for BRBNT, and the Symbol Digit Modalities test for SEFCI. The only clinical variable independently associated with impaired performance on these batteries was EDSS. Conclusions: Both cognitive batteries were well accepted and easy to administer. Administration time for SEFCI was significantly shorter than for BRBNT; however, alternative forms for serial evaluation are available only for BRBNT. The BRBNT was slightly more sensitive in detecting impairment by the criterion of poor performance on one or more tests. EDSS score was the only clinical variable independently associated with cognitive impairment.

Sign in / Sign up

Export Citation Format

Share Document